ID

12285

Descrizione

Official Title: Phase II Pharmacokinetic Study to Assess the Age-dependency in the Clearance of Doxorubicin in Paediatric Patients With Solid Tumours and Leukaemia Analyze pharmacokinetics of doxorubicin in children with cancer. Furthermore investigate the predictive role of troponin and natriuretic peptides for anthracycline-induced cardiotoxicity. https://clinicaltrials.gov/ct2/show/NCT01095926 NCT01095926

collegamento

https://clinicaltrials.gov/ct2/show/NCT01095926

Keywords

  1. 02/11/15 02/11/15 -
  2. 27/09/21 27/09/21 -
Caricato su

2 novembre 2015

DOI

Per favore, per richiedere un accesso.

Licenza

Creative Commons BY 4.0

Commenti del modello :

Puoi commentare il modello dati qui. Tramite i fumetti nei gruppi di articoli e articoli è possibile aggiungere commenti a quelli in modo specifico.

Commenti del gruppo di articoli per :

Commenti dell'articolo per :

Per scaricare i modelli di dati devi essere registrato. Per favore accesso o registrati GRATIS.

Pharmacokinetic Study of Doxorubicin in Children With Cancer DRKS00003787 NCT01095926

Registration

Registration
Descrizione

Registration

Date of birth
Descrizione

Date of birth

Tipo di dati

date

Alias
UMLS CUI [1]
C0421451
Date of consent first parent
Descrizione

Date of consent first parent

Tipo di dati

date

Alias
UMLS CUI [1]
C0600634
Date of consent second parent (UK: not necessary)
Descrizione

Date of consent second parent (UK: not necessary)

Tipo di dati

date

Alias
UMLS CUI [1]
C0600634
Sex
Descrizione

Sex

Tipo di dati

integer

Alias
UMLS CUI [1]
C0079399
Consent for blood sample for pharmacogenetic analysis
Descrizione

Consent for blood sample for pharmacogenetic analysis

Tipo di dati

integer

Alias
UMLS CUI [1]
C0021430
Date of diagnosis
Descrizione

Date of diagnosis

Tipo di dati

date

Alias
UMLS CUI [1]
C2316983
Tumour type
Descrizione

Tumour type

Wilms tumour
Descrizione

Wilms tumour SIOP Wilms tumour study group (e.g. SIOP WT 2001)

Tipo di dati

integer

Alias
UMLS CUI [1]
C0027708
Neuroblastoma
Descrizione

Neuroblastoma

Tipo di dati

integer

Alias
UMLS CUI [1]
C0027819
Ewing sarcoma
Descrizione

Ewing sarcoma

Tipo di dati

integer

Alias
UMLS CUI [1]
C0553580
Soft tissue sarcoma
Descrizione

Soft tissue sarcoma

Tipo di dati

integer

Alias
UMLS CUI [1]
C0334449
ALL
Descrizione

ALL

Tipo di dati

integer

Alias
UMLS CUI [1]
C0027651
Other
Descrizione

Other

Tipo di dati

integer

Alias
UMLS CUI [1]
C0027651
Doxorubicin administration: time of infusion
Descrizione

Doxorubicin administration: time of infusion

Is the planned infusion time in accordance with the above listed infusion time (taken from the protocol)?
Descrizione

Is the planned infusion time in accordance with the above listed infusion time (taken from the protocol)?

Tipo di dati

integer

Alias
UMLS CUI [1]
C0574032
Inclusion criteria
Descrizione

Inclusion criteria

Patient ≤ 17 years of age
Descrizione

Patient ≤ 17 years of age

Tipo di dati

boolean

Alias
UMLS CUI [1]
C0001779
Patient shall receive at least two cycles of doxorubicin
Descrizione

Patient shall receive at least two cycles of doxorubicin

Tipo di dati

boolean

Alias
UMLS CUI [1]
C0013089
Patient, parent(s) or legal representative has/have provided written informed consent to participate in the trial according to national regulations
Descrizione

Patient, parent(s) or legal representative has/have provided written informed consent to participate in the trial according to national regulations

Tipo di dati

boolean

Alias
UMLS CUI [1]
C0021430
Patient is enrolled in a national or European protocol - run by one of the study groups listed in the protocol - for treatment of Wilms tumours, neuroblastoma, soft tissue sarcoma, Ewing sarcoma or acute lymphatic leukaemia and is treated with doxorubicin according to that protocol Or Patient < 3 years enrolled or listed in any national or European study protocol for any paediatric malignancy. Treatment with doxorubicin has to be according to that protocol
Descrizione

Patient is enrolled in a national or European protocol

Tipo di dati

boolean

Alias
UMLS CUI [1]
C2348568
Life expectancy of at least 3 month
Descrizione

Life expectancy of at least 3 month

Tipo di dati

boolean

Alias
UMLS CUI [1]
C0023671
Karnofsky performance status of ≥ 70%
Descrizione

Karnofsky performance status of ≥ 70%

Tipo di dati

boolean

Alias
UMLS CUI [1]
C3829424
Additional blood withdrawal is acceptable for the patient
Descrizione

Additional blood withdrawal is acceptable for the patient

Tipo di dati

boolean

Alias
UMLS CUI [1]
C0005834
Assent of patient, if patient is able to (if not able: please enter „N.A.“)
Descrizione

Assent of patient, if patient is able to (if not able: please enter „N.A.“)

Tipo di dati

integer

Alias
UMLS CUI [1]
C1879749
Exclusion criterion
Descrizione

Exclusion criterion

Prior cardiac problems
Descrizione

Prior cardiac problems

Tipo di dati

boolean

Alias
UMLS CUI [1]
C0262402
Footer module
Descrizione

Footer module

Date of registration
Descrizione

Date of registration

Tipo di dati

date

Alias
UMLS CUI [1]
C2985881
Name Investigator
Descrizione

Name Investigator

Tipo di dati

integer

Alias
UMLS CUI [1]
C2826892
Signature Investigator
Descrizione

Signature Investigator

Tipo di dati

integer

Alias
UMLS CUI [1]
C2346576

Similar models

Registration

Name
genere
Description | Question | Decode (Coded Value)
Tipo di dati
Alias
Item Group
Registration
Date of birth
Item
Date of birth
date
C0421451 (UMLS CUI [1])
Date of consent first parent
Item
Date of consent first parent
date
C0600634 (UMLS CUI [1])
Date of consent second parent
Item
Date of consent second parent (UK: not necessary)
date
C0600634 (UMLS CUI [1])
Item
Sex
integer
C0079399 (UMLS CUI [1])
Code List
Sex
CL Item
male (1)
CL Item
female (2)
Item
Consent for blood sample for pharmacogenetic analysis
integer
C0021430 (UMLS CUI [1])
Code List
Consent for blood sample for pharmacogenetic analysis
CL Item
yes (1)
CL Item
no (2)
CL Item
"If yes, please document date of blood sample on page 39 „Pharmacogenetics“ (4)
Date of diagnosis
Item
Date of diagnosis
date
C2316983 (UMLS CUI [1])
Item Group
Tumour type
Item
Wilms tumour
integer
C0027708 (UMLS CUI [1])
Code List
Wilms tumour
CL Item
AVD (1)
CL Item
High Risk (2)
Item
Neuroblastoma
integer
C0027819 (UMLS CUI [1])
Code List
Neuroblastoma
CL Item
N4 (1)
CL Item
N6 (2)
CL Item
TVD (3)
CL Item
CADO (4)
Item
Ewing sarcoma
integer
C0553580 (UMLS CUI [1])
Code List
Ewing sarcoma
CL Item
VIDE (1)
CL Item
VAC (2)
CL Item
VAI (3)
Item
Soft tissue sarcoma
integer
C0334449 (UMLS CUI [1])
Code List
Soft tissue sarcoma
CL Item
10 - VAIA III (CWS (e.g. CWS-2002-P) )
CL Item
11 - High risk (EpSSG-Rhabdomyosarcoma (e.g. RMS 2005) )
CL Item
12 - IA (EpSSG-Soft tissue sarcoma (e.g. NRSTS 2005) )
Item
ALL
integer
C0027651 (UMLS CUI [1])
Code List
ALL
CL Item
I-BFM (e.g. ALL-BFM 2000) = 13 - Protocol II (1)
CL Item
AIEOP (e.g. LLA 2000) = 14 - Protocol II (2)
CL Item
AIEOP/I-BFM (AIEOP-BFM ALL2009) = 15 - Protocol II (3)
CL Item
SFCE (FRALLE 2000) = 16 - Consolidation ; 17 - Intensification (4)
CL Item
MRC (e.g. UKALL 2003) = 18 - Delayed Intensification (5)
Item
Other
integer
C0027651 (UMLS CUI [1])
Code List
Other
CL Item
To include a patient with another tumour type is only possible if the patient is younger than 3 years! (1)
CL Item
Please contact the national study manager to verify if patient is eligible. (2)
Item Group
Doxorubicin administration: time of infusion
Item
Is the planned infusion time in accordance with the above listed infusion time (taken from the protocol)?
integer
C0574032 (UMLS CUI [1])
Code List
Is the planned infusion time in accordance with the above listed infusion time (taken from the protocol)?
CL Item
Yes (protocol specific sampling sheets will be provided) (1)
CL Item
No, deviations are planned (one of three flexible standard sheets will be provided) (2)
CL Item
If no: administered infusion time: ≤ 0.5 h; > 0.5 h - < 12 h; ≥ 12 h (3)
Item Group
Inclusion criteria
Patient ≤ 17 years of age
Item
Patient ≤ 17 years of age
boolean
C0001779 (UMLS CUI [1])
Patient shall receive at least two cycles of doxorubicin
Item
Patient shall receive at least two cycles of doxorubicin
boolean
C0013089 (UMLS CUI [1])
Patient, parent(s) or legal representative has/have provided written informed consent to participate in the trial according to national regulations
Item
Patient, parent(s) or legal representative has/have provided written informed consent to participate in the trial according to national regulations
boolean
C0021430 (UMLS CUI [1])
Patient is enrolled in a national or European protocol
Item
Patient is enrolled in a national or European protocol - run by one of the study groups listed in the protocol - for treatment of Wilms tumours, neuroblastoma, soft tissue sarcoma, Ewing sarcoma or acute lymphatic leukaemia and is treated with doxorubicin according to that protocol Or Patient < 3 years enrolled or listed in any national or European study protocol for any paediatric malignancy. Treatment with doxorubicin has to be according to that protocol
boolean
C2348568 (UMLS CUI [1])
Life expectancy of at least 3 month
Item
Life expectancy of at least 3 month
boolean
C0023671 (UMLS CUI [1])
Karnofsky performance status of ≥ 70%
Item
Karnofsky performance status of ≥ 70%
boolean
C3829424 (UMLS CUI [1])
Additional blood withdrawal is acceptable for the patient
Item
Additional blood withdrawal is acceptable for the patient
boolean
C0005834 (UMLS CUI [1])
Item
Assent of patient, if patient is able to (if not able: please enter „N.A.“)
integer
C1879749 (UMLS CUI [1])
Code List
Assent of patient, if patient is able to (if not able: please enter „N.A.“)
CL Item
Yes (1)
CL Item
No (2)
CL Item
N.A. (3)
CL Item
If assent is given: Date of patient assent (4)
Item Group
Exclusion criterion
Prior cardiac problems
Item
Prior cardiac problems
boolean
C0262402 (UMLS CUI [1])
Item Group
Footer module
Date of registration
Item
Date of registration
date
C2985881 (UMLS CUI [1])
Name Investigator
Item
Name Investigator
integer
C2826892 (UMLS CUI [1])
Signature Investigator
Item
Signature Investigator
integer
C2346576 (UMLS CUI [1])

Si prega di utilizzare questo modulo per feedback, domande e suggerimenti per miglioramenti.

I campi contrassegnati da * sono obbligatori.

Do you need help on how to use the search function? Please watch the corresponding tutorial video for more details and learn how to use the search function most efficiently.

Watch Tutorial